Among 2 analysts covering Extendicare Inc (TSE:EXE), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Extendicare Inc had 8 analyst reports since August 10, 2015 according to SRatingsIntel. The stock has “Outperform” rating by IBC on Friday, June 17. As per Monday, August 10, the company rating was maintained by TD Securities. IBC downgraded EXTENDICARE INC (TSE:EXE) on Monday, April 3 to “Neutral” rating. See EXTENDICARE INC (TSE:EXE) latest ratings:
03/04/2017 Broker: IBC Old Rating: Outperform New Rating: Neutral Downgrade
02/03/2017 Broker: TD Securities Rating: Hold Old Target: $9.50 New Target: $10.00 Target Down
Analysts expect Merck & Co., Inc. (NYSE:MRK) to report $0.83 EPS on May, 2 before the open.They anticipate $0.06 EPS change or 6.74% from last quarter’s $0.89 EPS. MRK’s profit would be $2.27B giving it 18.77 P/E if the $0.83 EPS is correct. After having $0.89 EPS previously, Merck & Co., Inc.’s analysts see -6.74% EPS growth. The stock decreased 0.40% or $0.25 on April 28, reaching $62.33. About shares traded. Merck & Co., Inc. (NYSE:MRK) has declined 1.09% since September 22, 2016 and is downtrending. It has underperformed by 10.60% the S&P500.
Merck & Co., Inc. is a global healthcare company. The company has market cap of $170.20 billion. The Firm offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It has a 44.44 P/E ratio. It operates through four divisions: Pharmaceutical, Animal Health, Healthcare Services and Alliances.
Among 17 analysts covering Merck & Co. Inc. (NYSE:MRK), 12 have Buy rating, 1 Sell and 4 Hold. Therefore 71% are positive. Merck & Co. Inc. had 35 analyst reports since August 13, 2015 according to SRatingsIntel. The company was upgraded on Thursday, October 13 by Bank of America. As per Thursday, January 12, the company rating was upgraded by Piper Jaffray. Guggenheim upgraded the stock to “Buy” rating in Thursday, January 12 report. Berenberg upgraded the shares of MRK in report on Thursday, August 27 to “Hold” rating. As per Tuesday, December 1, the company rating was upgraded by Barclays Capital. Bank of America downgraded the stock to “Neutral” rating in Wednesday, January 27 report. The firm has “Overweight” rating by JP Morgan given on Monday, September 21. Argus Research maintained Merck & Co., Inc. (NYSE:MRK) on Tuesday, November 17 with “Buy” rating. The rating was initiated by Societe Generale with “Hold” on Wednesday, September 30. The company was upgraded on Tuesday, August 18 by BNP Paribas.
